Administration of the Comirnaty® Vaccine in a Fractional Regimen in Two Patients with Immediate Acute Urticaria after the First Dose

Antón Gironés M1, Montoro Lacomba J2, Navarro Cascales T3, Lindo Gutarra M3, Marco de la Calle FM4

1Servicio de Alergología. Hospital Universitario del Vinalopó. Elche (Alicante). Facultad de Medicina. Universidad Católica San Antonio de Murcia
2Unidad de Alergia. Hospital de Liria (Valencia). Facultad de Medicina. Universidad Católica de Valencia “San Vicente Martir”
3Servicio de Alergología. Hospital Universitario del Vinalopó. Elche (Alicante)
4Sección de Inmunología. Hospital General Universitario de Alicante

Corresponding author

Mónica Antón Gironés

Calle Alicante, 21-1B San Vicente del Raspeig 03690 (Alicante)

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0717
Key words: Comirnaty® vaccine. SARS-COV2. Immediate urticaria. Fractional administration. Polyethylene glycol.

Palabras clave: Vacuna Comirnaty®. SARS-COV2. Urticaria inmediata.
Administración fraccionada. Polietilenglicol.

In Spain, since vaccination against SARS-CoV2 began on December 27, 2020, the Spanish Agency for Medicines and Health Products (AEMPS) has received 1,537 reports of adverse events with Comirnaty®[1]. Eight cases (0.52%) were reported with criteria for anaphylaxis. In 63% of cases symptoms began within the first 30 minutes after vaccination (63%) and 75% of cases required epinephrine. EAACI (European Academy of Allergy and Clinical Immunology) and SEAIC (Spanish Society of Allergy and Clinical Immunology), have contraindicated Comirnaty® administration only in patients who have had an allergic reaction to a previous dose or to any of its components [2,3,4].

Of the components of the Pfizer-BioNTech vaccine (Comirnaty®), polyethylene glycol (PEG) is considered a possible responsible for allergic reactions, although it has not yet been confirmed [5].

PEG 2000 is an excipient of the Comirnaty® vaccine which is part of the lipid nanoparticle where the mRNA is carried to ensure its preservation. PEGs are hydrophilic polymers with sensitization capacity demonstrated with immediate-type hypersensitivity reported cases in a MW range from 300 to 20000 g/mol [6]. It is widely used as an excipient in daily use products, including medicines, cosmetics or food, but it is the first time that PEG has been included as an excipient in a vaccine, and it is
different from the one more commonly used in other medical devices in its MW and by its coformulation as a stabilizing portion of a liposome [7].

In 1978 the first case of allergic contact dermatitis due to PEG [8] was described, but it was in 2008 when the first cases of immediate allergy [9] (including anaphylaxis) were reported; in recent years, a great number of allergic reactions caused by PEG have been described [6,10].

The Vinalopó University Hospital in Elche (Alicante) vaccinated its staff from January 8, 2021 with the Comirnaty® vaccine. Of the total of 1136 doses administered, there were two cases of immediate urticaria within the first 20 minutes after administration, which represent an incidence of 0.18%. One of the patients had a systemic reaction (patient 1) and the other a located reaction in neckline (patient 2).

Case 1: 57-years-old female patient with a history of allergy to quinolones, mild intermittent pollen rhinitis and recurrent acute urticaria with negative allergy study, tryptase included.

Case 2: 40-years-old male patient, with a history of adverse reaction with cephalosporin and acetylsalicylic acid, mild intermittent asthma due to mites and recurrent acute urticaria with negative allergological study, tryptase included.

Both were treated with oral antihistamines and patient 1 also received systemic intramuscular corticosteroids (methylprednisolone 60 mg), which resolved in less than 1 hour in both patients.

Considering the recommendations of the EAACI [11], as well as the experience with adverse reactions with other vaccines [12], we carried out a complete allergological
study in both patients following the diagnostic-therapeutic algorithm summarized in the Figure. The same skin tests with the vaccine and PEGs were performed on 5 healthy controls, with negative results.

Basophil activation test (BAT; Basotest, Glycotope Biotechnology, Germany) [13] was carried out with COVID vaccine (Comirnaty®, as is and 3 additional serial 1/10 dilutions), and PEG 400, 1500, 4000 and 20000 (Merck, Germany, at 10 mg/ml and five serial 1/10 dilutions). Cut off was set at 5% CD63 induction over negative control. BAT with Comirnaty® was negative in both patients at all tested dilutions. Patient 2 showed weak positive results with PEG 400 (0.01 mg/ml 10% and 0.001 mg/ml 7%); PEG 4000 (1 mg/ml 7%) and PEG 20000 (0.001 mg/ml 9%). Healthy controls were negative.

The study of the hypersensitivity reactions with a possible involvement of PEG is complicated by the difficulties in setting up of specific IgE assays, so that diagnostic work up is generally limited to “in vivo” tests. PEG may induce the production of IgG and IgM antibodies both in patients showing PEG-related adverse effects and in healthy individuals [13,14]. These antibodies may also mediate immune reactions to PEG involving activation of the complement system. PEG compounds are usually linear or branched polymers. The epitope of PEGs is not known, and there is heterogeneity in their allergenic capacity [6].

Taking into account the positive results obtained in the study by prick and ID testing for both patients, the compatible symptoms with an immediate allergic reaction, the need to safely receive the second dose, and the lack of previous experience with Comirnaty®, we decided to perform the vaccine administration by means of a fractional regimen with
Premedication as follow. First, 60 mg of methylprednisolone iv, 5mg of dextchlorpheniramine iv, 150 mg of ranitidine iv and 10mg of oral montelukast; 30 minutes later, administration of the second dose of Comirnaty® divided into 3 doses of 0.1 ml, with an interdose period of 1 hour and an additional 1 hour of observation after the last dose administered. Both patients presented itching 20 minutes after the first and second doses, without hives and with spontaneous disappearance before administration next dose. All doses were completed without immediate or late incidents.

As conclusion, a fractional regimen for the administration of the second dose of Comirnaty vaccine has proven useful in two patients with immediate allergic reaction during administration of their first dose.

**Funding**

The authors declare that no funding was received for the present study.

**Conflicts of interest**

The authors have no conflict of interests to declare.
References


Figure legend

**FIGURE: RESULTS OF THE STUDY**

<table>
<thead>
<tr>
<th>Patient 1</th>
<th>Patient 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NEGATIVE RESULTS</strong></td>
<td><strong>POSITIVE RESULTS</strong></td>
</tr>
<tr>
<td>Prick test with vaccine</td>
<td>-</td>
</tr>
<tr>
<td>ID with vaccine 1/1000 and 1/10</td>
<td>-</td>
</tr>
<tr>
<td>Prick test with PEG 400</td>
<td>-</td>
</tr>
<tr>
<td>ID with PEG 400 1/1000 and 1/10000</td>
<td>-</td>
</tr>
<tr>
<td>BAT with vaccine and PEG 400, 1500, 4000 and 20000</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>